Amifostine: chemotherapeutic and radiotherapeutic protective effects

Expert Opinion on Pharmacotherapy
V Santini

Abstract

Amifostine (Ethyoltrade mark, Alza Pharmaceuticals) is an inorganic thiophosphate cytoprotective agent known chemically as ethanethiol, 2-[3- aminopropyl)amino]dihydrogen phosphate. It is a prodrug of free thiol (WR-1065) that may act as a scavenger of free radicals generated in tissues exposed to cytotoxic drugs and binds to reactive metabolites of such drugs. Amifostine was originally developed as a radioprotective agent in a classified nuclear warfare project. Following declassification of the project it was evaluated as a cytoprotective agent against toxicity of the alkylating drugs and cisplatin. Differences in the alkaline phosphatase concentration of normal versus tumour tissues can result in greater conversion of amifostine in normal tissues. Inside the cell, WR-1065 provides an alternative target to DNA and RNA for the reactive molecules of alkylating or platinum agents and acts as a potent scavenger of the oxygen free radicals induced by ionizing radiation and some chemotherapy agents. Preclinical animal studies have demonstrated that the administration of amifostine protects against a variety of chemotherapy-related toxicities including cisplatin-induced nephrotoxicity, cisplatin-induced neurotoxicity, cyclophosphami...Continue Reading

References

Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·N R HunterL Milas
Jan 1, 1992·Cancer Chemotherapy and Pharmacology·J A van LaarG J Peters
Aug 1, 1986·International Journal of Radiation Oncology, Biology, Physics·B Nagy, D J Grdina
Aug 1, 1986·International Journal of Radiation Oncology, Biology, Physics·L S ConstineM Kligerman
Jun 1, 1988·International Journal of Radiation Oncology, Biology, Physics·M M KligermanP Rubin
Jan 1, 1988·Pharmacology & Therapeutics·L M ShawM M Kligerman
Jan 1, 1988·Pharmacology & Therapeutics·L FleckensteinD J Mangold
Apr 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D GloverM M Kligerman
Aug 1, 1986·International Journal of Radiation Oncology, Biology, Physics·L M ShawM M Kligerman
Aug 1, 1986·International Journal of Radiation Oncology, Biology, Physics·D GloverM M Kligerman
Apr 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D GloverD Guerry
Sep 1, 1984·International Journal of Radiation Oncology, Biology, Physics·J F UtleyR C Fahey
Sep 1, 1984·International Journal of Radiation Oncology, Biology, Physics·M M KligermanR L Goodman
Sep 1, 1984·International Journal of Radiation Oncology, Biology, Physics·J H GlickM M Kligerman
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R L Capizzi, W Oster
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M TreskesW J van der Vijgh
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H SchillerW Berry
Jan 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·W J van der Vijgh, A E Korst
Jan 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R M Bukowski
Jan 1, 1996·Cancer Chemotherapy and Pharmacology·A E KorstW J van der Vijgh
Apr 1, 1997·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·J A Foster-Nora, R Siden
Jul 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A AvilésM J Nambo
Apr 16, 1998·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·J BüntzelM Glatzel
Jul 8, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BüntzelM Glatzel
Aug 14, 1998·Journal of Pediatric Hematology/oncology·C M BureshM Shafer
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L HensleyD G Pfister
May 17, 2000·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·C GridelliL Manzione
Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M I KoukourakisV Georgoulias
Aug 10, 2000·Radiation Research·D MurrayM J Allalunis-Turner

❮ Previous
Next ❯

Citations

Dec 13, 2006·Bulletin of Experimental Biology and Medicine·M V VasinL A Semenova
May 12, 2005·Blood Reviews·Daniel V T Catenacci, Gary J Schiller
Feb 6, 2004·Seminars in Cancer Biology·Alison M JohnRose Ann Padua
Oct 12, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ourania Nicolatou-GalitisUNKNOWN Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (
Sep 19, 2008·Expert Opinion on Drug Metabolism & Toxicology·Loren K Mell, Benjamin Movsas
Nov 28, 2013·Emergency Medicine Clinics of North America·Zhanna LivshitsSilas W Smith
Aug 31, 2002·Medical and Pediatric Oncology·P A Voûte
Feb 19, 2008·Cancer Treatment Reviews·Andreas A ArgyriouHaralabos P Kalofonos
May 4, 2011·Environmental and Molecular Mutagenesis·Wieslawa KosinskaJoseph B Guttenplan
Oct 28, 2009·Journal of Biomedicine & Biotechnology·S Ortega-GutiérrezJ J García
Sep 7, 2002·Cancer·Darren R HargraveSylvain Baruchel
Oct 8, 2009·Dose-response : a Publication of International Hormesis Society·E A Prieto GonzálezGonzález S Sánchez
Apr 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James J Lee, Sandra M Swain
Mar 7, 2002·Cancer Practice·J S Jacobson, W J Verret
Nov 11, 2008·Retina·Edward ChaumKenneth W Tobin
Jan 23, 2003·The Journal of Pharmacology and Experimental Therapeutics·Efstathia GiannopoulouEvangelia Papadimitriou
Sep 19, 2019·Expert Opinion on Drug Safety·Vijay K Singh, Thomas M Seed
Nov 19, 2019·Current Cancer Drug Targets·Keywan MortezaeeAhmed E Musa
Mar 6, 2004·Pharmacological Reviews·Martijn RooseboomNico P E Vermeulen
Jan 6, 2004·Free Radical Research·Efstathia Giannopoulou, Evangelia Papadimitriou
Mar 18, 2005·Journal of Medicinal Chemistry·Kristen L ArientiJ Guy Breitenbucher

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.